Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 15, 2026
TickeronGET DAILY SIGNALS
Metagenomi (MGX) Stock Slips -12% Over 30 Days as Clinical Milestone Emerges

Metagenomi (MGX) Stock Slips -12% Over 30 Days as Clinical Milestone Emerges

Key Takeaways

  • MGX shares declined roughly 12% over the last 30 days, falling from a close of about $0.78 in mid-October to about $0.69 per share.
  • The pullback extends a broader slide: the stock is down about 44% over the trailing quarter and roughly 63% over the past year.
  • On November 10, 2026, the U.S. FDA cleared the Investigational New Drug (IND) application for MGX-001 in hemophilia A, triggering a brief intraday pop of roughly 11% that quickly faded.
  • Third-quarter 2026 results beat reduced expectations, with a GAAP loss of $0.56 per share, while collaboration revenue fell about 75% year over year as legacy partnership income wound down.
  • Metagenomi held approximately $101.7 million in cash, cash equivalents, and marketable securities as of September 30, 2026, which management expects to fund operations into 2028.
  • Near-term catalysts include initiation of the INTEGR8 Phase 1/2 trial (targeted for the first half of 2027) and initial clinical data (targeted for the second half of 2027).
  • For deeper metrics, explore Metagenomi's Price Targets, Earnings, and Forecast pages.
  • Explore Trending AI Robots to review AI-driven trading strategies across the market.

Metagenomi (MGX) and Its Place in Genome Editing

Metagenomi Therapeutics, Inc. is an in vivo genome editing company that uses metagenomics to find and develop new CRISPR tools. The focus is on programs with clear biology and regulatory paths, with the goal of fixing genetic mutations inside the body. Its main candidate, MGX-001, is a one-time therapy meant to deliver lasting Factor VIII activity for people with hemophilia A. I follow MGX because of its unique gene-editing approach and the upcoming shift into clinical testing.

How MGX Performed Over the Past Month and Quarter

In the last 30 days, MGX fell roughly 12%, moving from a close of $0.784 on October 16, 2026, to $0.6917 on November 13, 2026. The path was uneven, with a sharp drop in mid-October, a quick lift after the FDA news, and then a retreat. Over the trailing quarter the decline reached about 44% from levels near $1.23 in mid-August, leaving the shares far below the $15.00 IPO price from February 2024.

What Shaped the Recent Price Action

The 30-day period started with a mid-October re-rating that took the stock from around $1.02 down to roughly $0.78 amid broader pressure on small-cap biotech names. On November 10, 2026, the FDA cleared the IND for MGX-001, opening the way for the first human trial; shares rose about 11% intraday before giving back the gain. That same day the company posted third-quarter results showing a GAAP loss of $0.56 per share that topped lowered estimates, collaboration revenue of $2.18 million (down about 75% year over year), and cash of about $101.7 million expected to last into 2028. Wells Fargo kept its Buy rating and $7.00 target. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Profit-taking and revenue concerns appear to have outweighed the regulatory step in the sessions that followed.

Drivers Behind the Quarterly Decline

The roughly 44% drop over three months reflects the company’s move away from legacy partnerships and toward its own pipeline, which has not yet reached the clinic. Ongoing losses and cash use have kept dilution worries alive, and the slide below $1 raises questions about Nasdaq bid-price rules. Wider caution around early-stage gene-editing stocks added to the pressure even as MGX-001 moved closer to human testing.

Key Events Investors Are Watching

The main items on the horizon are clinical and financial. I’m watching closely for the start of the INTEGR8 Phase 1/2 trial for MGX-001, targeted for the first half of 2027, and the first safety and Factor VIII data expected in the second half of 2027. Preclinical data on MGX-001 is also due at the American Society of Hematology meeting. Cash burn, the $101.7 million balance, and any new financing will stay in focus, along with the stock’s position below $1 and the consensus price target near $7.00. This information is provided for educational purposes and is not investment advice.

Using Tickeron AI Tools for Market Context

In my own research I often turn to Tickeron’s AI tools to compare names like MGX against peers and to review automated trading approaches. The platform’s data-driven signals help put price moves and sector trends into perspective without replacing fundamental analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MGX

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


MGX sees its Stochastic Oscillator climbs out of oversold territory

On November 06, 2026, the Stochastic Oscillator for MGX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 30 instances where the indicator left the oversold zone. In 26 of the 30 cases the stock moved higher in the following days. This puts the odds of a move higher at over 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MGX's RSI Oscillator exited the oversold zone, 14 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.

The Moving Average Convergence Divergence (MACD) for MGX just turned positive on October 29, 2026. Looking at past instances where MGX's MACD turned positive, the stock continued to rise in 18 of 22 cases over the following month. The odds of a continued upward trend are 82%.

Following a +4.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGX advanced for three days, in 88 of 111 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

MGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for MGX entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.238) is normal, around the industry mean (3.498). P/E Ratio (-0.285) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (3.195) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. MGX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -18%. PEPG experienced the highest price growth at 77%, while ZURA experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
5959 Horton Street
Phone
+1 510 871-4880
Employees
119
Web
https://metagenomi.co
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.
ACHR fell -7.44% in Monday's regular session, sliding from Friday's $4.03 close to $3.73 shortly after 10 a.m. ET — a third consecutive daily decline that pushed shares back toward their November 5 low. No verified news or fundamental catalyst found for today's leg lower; the selling extends the de-rating that followed Q3 results — revenue of just $5.1 million, a net loss widening 111% to $274.6 million, and price-target cuts from Cantor Fitzgerald, Needham and Canaccord.